[메디칼업저버 신형주 기자] GC Cell presented the non-clinical research results of CD5 CAR-NK and Immunecell LCD RWD at the annual conference of the American Association for Cancer Research (AACR) held in San Diego, California, USA from April 5th to 10th publication.
The AACR conference is considered one of the three most prestigious conferences in the field of oncology in the world, along with the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO).
Latest research results and innovative treatments will be discussed.
T-cell lymphoma is a malignant tumor with few treatment options other than chemotherapy, and is a disease with a large unmet medical need.
Some patients use Adcetris, which targets CD30, but its application is limited due to the multiple subtypes and low expression of CD30.
GC Cell is developing a treatment called ‘GL205/GCC2005’ in which allogeneic cord blood-derived NK cells contain a chimeric antigen receptor (CAR) that targets CD5 expressed in T-cell lymphoma.
We plan to publish non-clinical research results through AACR 2024.
‘GL205/GCC2005’ is applicable to a wide range of patients by targeting CD5 which is expressed in most T cells, and is a new approach that can overcome the manufacturing and culture problems of current CAR-T cell therapy.
GL205/GCC2005, which maximizes NK cell activity by applying CG Cell’s proprietary CAR-NK platform technology, exhibits CAR expression with high efficiency over 90%, and exhibits high killing capacity and increased cytokine secretion against CD5+ tumor cells.
In various CD5-positive animal disease models, GL205/GCC2005 showed tumor suppressive ability and improved survival time, and its efficacy was confirmed even at low doses, and the in vivo effect was improved by repeated administration.
The short persistence of NK cells, noted as a limitation compared to CAR-T treatments, showed a significant improvement of at least 3 to 6 months.
The excellent cancer cell-killing properties and improved persistence in the body confirmed in non-clinical results raise expectations for the efficacy of GL205/GCC2005 in clinical trials, and show potential as a breakthrough new drug for T-cell lymphoma.
In addition, in this AACR, the research results of a clinical research investigator (IIT) led by Professor Choi Jong-kwon from the Department of Hematology and Oncology of Konyang University Hospital were adopted.
A poster is published on the results of a real-world data (RWD) analysis on the efficacy and safety of the combined administration of Immunecell LC with a targeted therapy or an already approved immunotherapy.
A GC Cell official said, “We have confirmed that GL205/GCC2005 can effectively target CD5 in malignant T-cell lymphoid tumors. This could be a new treatment option for T-cell lymphoma patients for whom previously approved treatments are limited.” “It suggests,” he said.
He added, “This presentation at AACR 2024 is an important opportunity to share research results on a global stage,” adding, “It raises expectations for future clinical research on GL205/GCC2005, which is to be submit for IND this year. “
Meanwhile, GC Cell analyzed the patient group showing clinically significant improvement and various combination options through this RWD related to the combined administration of Immunecell LC, thereby providing evidence and a good foundation for future demonstration expansion strategies.
LCD Cell Immunity is an anticancer immune cell therapy that has proven effective in solid cancers, including hepatocellular carcinoma, and has been designated an orphan drug (ODD) by the FDA.
It was approved as an orphan drug for the treatment of hepatocellular carcinoma, glioblastoma, and pancreatic cancer.
Immune Cell LCD’s main ingredient is autologous blood-derived T cells, which enhance the function of killer cells that target cancer cells by isolating immune cells from the patient’s blood and culturing the cells for 2 to 3 weeks.
In addition, it was approved as a treatment after curative treatment for hepatocellular carcinoma based on the results of reducing the risk of recurrence by 37% and mortality by 79% compared to the control group in a large-scale phase 3 clinical trial for patients with early hepatocellular carcinoma.
No serious adverse reactions of grade 3 or higher were observed. Recently, data was obtained on 10,000 cumulative treatments.
#Cell #announces #results #nonclinical #CD5 #CARNK #study #AACR
